

# Kimberly K Scarsi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2110688/publications.pdf>

Version: 2024-02-01

66  
papers

1,502  
citations

331538

21  
h-index

360920

35  
g-index

68  
all docs

68  
docs citations

68  
times ranked

1899  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of vaccination rates in people living with HIV followed at a specialty care clinic. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 791-796.	1.4	8
2	The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?. <i>Journal of the International Association of Providers of AIDS Care</i> , 2021, 20, 232595822110090.	0.6	35
3	InÂvitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. <i>HIV Medicine</i> , 2021, 22, 898-906.	1.0	1
4	Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 710-717.	1.3	1
5	A Call to Action: The Role of Antiretroviral Stewardship in Inpatient Practice, a Joint Policy Paper of the Infectious Diseases Society of America, HIV Medicine Association, and American Academy of HIV Medicine. <i>Clinical Infectious Diseases</i> , 2020, 70, 2241-2246.	2.9	16
6	Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review. <i>Clinical Pharmacokinetics</i> , 2020, 59, 137-154.	1.6	24
7	Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics. <i>Scientific Reports</i> , 2020, 10, 12565.	1.6	14
8	Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study. <i>Lancet Microbe</i> , The, 2020, 1, e200-e208.	3.4	74
9	HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety. <i>Drugs</i> , 2020, 80, 1649-1676.	4.9	62
10	Drug Interactions with Gender-Affirming Hormone Therapy: Focus on Antiretrovirals and Direct Acting Antivirals. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 565-581.	1.5	11
11	Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1085-1107.	1.6	31
12	Chasing the cabotegravir tail: implications for prevention. <i>Lancet HIV</i> ,the, 2020, 7, e451-e453.	2.1	6
13	Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 45-53.	0.7	9
14	Response to Dong et al.. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa032.	0.4	0
15	Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1242-1249.	1.3	17
16	Acceptability and Feasibility of a Pharmacist-Led Human Immunodeficiency Virus Pre-Exposure Prophylaxis Program in the Midwestern United States. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.4	56
17	Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3003-3010.	1.3	13
18	Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study. <i>Lancet HIV</i> ,the, 2019, 6, e601-e612.	2.1	14

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2707-2715.	1.3	7
20	A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda. <i>Aids</i> , 2019, 33, 1995-2004.	1.0	8
21	Low Rate of Sex-specific Analyses in Presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) Meeting, 2018: Room to Improve. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e158-e160.	0.9	9
22	Normalization of cell associated antiretroviral drug concentrations with a novel RPP30 droplet digital PCR assay. <i>Scientific Reports</i> , 2018, 8, 3626.	1.6	24
23	Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1004-1012.	1.3	15
24	Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. <i>Aids</i> , 2018, 32, 761-765.	1.0	61
25	Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1084, 106-112.	1.2	12
26	Midwest pharmacists' familiarity, experience, and willingness to provide pre-exposure prophylaxis (PrEP) for HIV. <i>PLoS ONE</i> , 2018, 13, e0207372.	1.1	20
27	A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction. <i>BMC Infectious Diseases</i> , 2018, 18, 310.	1.3	2
28	Drug Interactions in HIV: Nucleoside, Nucleotide, and Nonnucleoside Reverse Transcriptase Inhibitors and Entry Inhibitors. , 2018, , 297-356.		1
29	Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors. <i>Clinical Pharmacokinetics</i> , 2017, 56, 25-40.	1.6	80
30	The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 529-536.	2.3	28
31	Efavirenz decreases etonogestrel exposure. <i>Aids</i> , 2017, 31, 1965-1972.	1.0	35
32	Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines. <i>Journal of the International AIDS Society</i> , 2017, 20, 21396.	1.2	20
33	Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort. <i>Clinical Infectious Diseases</i> , 2016, 62, civ928.	2.9	12
34	Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV. <i>Drug Safety</i> , 2016, 39, 1053-1072.	1.4	41
35	Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. <i>Clinical Infectious Diseases</i> , 2016, 62, 675-682.	2.9	75
36	Dolutegravir-induced colitis in an HIV-infected patient. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 281-282.	1.3	5

#	ARTICLE	IF	CITATIONS
37	Pharmacist-provided rapid HIV testing in two community pharmacies. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2015, 55, 81-88.	0.7	63
38	Consumer interest in community pharmacy HIV screening services. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2015, 55, 67-72.	0.7	21
39	Impact of an Electronic Medical Record on the Incidence of Antiretroviral Prescription Errors and HIV Pharmacist Reconciliation on Error Correction among Hospitalized HIV-Infected Patients. <i>Antiviral Therapy</i> , 2015, 20, 555-559.	0.6	10
40	Antiretroviral Pharmacokinetics in Pregnant Women. <i>Pharmacotherapy</i> , 2015, 35, 838-855.	1.2	31
41	Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7852-7856.	1.4	14
42	Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration. <i>Clinical Drug Investigation</i> , 2015, 35, 275-280.	1.1	2
43	Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1370-1376.	1.3	18
44	Clinical implications of antiretroviral drug interactions with warfarin: a case-control study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1360-1363.	1.3	15
45	Optimizing Treatment Switch for Virologic Failure during First-Line Antiretroviral Therapy in Resource-Limited Settings. <i>Journal of the International Association of Providers of AIDS Care</i> , 2013, 12, 236-240.	0.6	7
46	Protein Binding of Lopinavir and Ritonavir During 4 Phases of Pregnancy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 51-58.	0.9	37
47	Accumulation of Protease Mutations among Patients Failing Second-Line Antiretroviral Therapy and Response to Salvage Therapy in Nigeria. <i>PLoS ONE</i> , 2013, 8, e73582.	1.1	36
48	Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-6.	0.3	12
49	Combination Nucleoside/Nucleotide Reverse Transcriptase Inhibitors for Treatment of HIV Infection. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 65-79.	0.9	18
50	Low incidence of renal impairment observed in tenofovir-treated patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1120-1126.	1.3	21
51	Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV. <i>Advances in Therapy</i> , 2010, 27, 1-16.	1.3	16
52	Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 345-350.	0.9	23
53	Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 94-95.	1.1	14
54	Chronic Hepatitis B Infection: Principles of Therapy. <i>Journal of Pharmacy Practice</i> , 2009, 22, 359-387.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Effect of Differences in MIC Values on Clinical Outcomes in Patients with Bloodstream Infections Caused by Gram-Negative Organisms Treated with Levofloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1074-1079.	1.4	37
56	Hepatotoxicity Associated with Long- versus Short-Course HIV-Prophylactic Nevirapine Use. <i>Drug Safety</i> , 2009, 32, 147-158.	1.4	41
57	Empiric antibiotic selection for infectious emergencies: Bacterial pneumonia, meningitis and sepsis. <i>Drugs of Today</i> , 2009, 45, 379.	0.7	8
58	Adjustment of Antimicrobial Dosages for Continuous Venovenous Hemofiltration Based on Patient-Specific Information. <i>Clinical Infectious Diseases</i> , 2006, 42, 436-437.	2.9	13
59	Lack of effect of fluoroquinolone resistance on mortality in subjects with <i>Pseudomonas aeruginosa</i> bacteraemia. <i>Journal of Infection</i> , 2006, 52, 105-110.	1.7	7
60	Impact of Inactive Empiric Antimicrobial Therapy on Inpatient Mortality and Length of Stay. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3355-3360.	1.4	39
61	Elevated Plasma Concentrations of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors in Patients Coinfected with Human Immunodeficiency Virus and Hepatitis B or C: Case Series and Literature Review. <i>Pharmacotherapy</i> , 2005, 25, 1068-1072.	1.2	9
62	Effect of on-call infectious-diseases pharmacists on antibiotic expenditures. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1967-1968.	0.5	3
63	Breakthrough Candida Infections in Patients Receiving Voriconazole. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1342-1345.	0.9	15
64	The impact of gender and pregnancy on antiretroviral therapy for HIV: pharmacokinetic and disease-related differences. <i>Journal of Gender-specific Medicine</i> , 2003, 6, 7-16.	0.1	0
65	Pharmacist participation in medical rounds reduces medication errors. <i>American Journal of Health-System Pharmacy</i> , 2002, 59, 2089-2092.	0.5	105
66	The Use of ACE Inhibitors as Renoprotective Agents in Medicaid Patients with Diabetes. <i>Annals of Pharmacotherapy</i> , 2000, 34, 1002-1006.	0.9	20